- Home
- SOL vs MNPR Comparison
SOL vs MNPR Comparison
Compare SOL & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOL
- MNPR
- Stock Information
- Founded
- SOL 2005
- MNPR 2014
- Country
- SOL United States
- MNPR United States
- Employees
- SOL N/A
- MNPR N/A
- Industry
- SOL Semiconductors
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- SOL Technology
- MNPR Health Care
- Exchange
- SOL Nasdaq
- MNPR Nasdaq
- Market Cap
- SOL 97.4M
- MNPR 113.5M
- IPO Year
- SOL 2008
- MNPR 2019
- Fundamental
- Price
- SOL $1.83
- MNPR $25.82
- Analyst Decision
- SOL Buy
- MNPR Strong Buy
- Analyst Count
- SOL 3
- MNPR 3
- Target Price
- SOL $3.83
- MNPR $27.33
- AVG Volume (30 Days)
- SOL 212.0K
- MNPR 101.2K
- Earning Date
- SOL 11-14-2024
- MNPR 11-08-2024
- Dividend Yield
- SOL N/A
- MNPR N/A
- EPS Growth
- SOL N/A
- MNPR N/A
- EPS
- SOL N/A
- MNPR N/A
- Revenue
- SOL $102,489,000.00
- MNPR N/A
- Revenue This Year
- SOL N/A
- MNPR N/A
- Revenue Next Year
- SOL $46.42
- MNPR N/A
- P/E Ratio
- SOL N/A
- MNPR N/A
- Revenue Growth
- SOL 25.98
- MNPR N/A
- 52 Week Low
- SOL $1.41
- MNPR $1.55
- 52 Week High
- SOL $3.00
- MNPR $38.50
- Technical
- Relative Strength Index (RSI)
- SOL 43.76
- MNPR 57.88
- Support Level
- SOL $1.75
- MNPR $22.61
- Resistance Level
- SOL $1.98
- MNPR $32.20
- Average True Range (ATR)
- SOL 0.13
- MNPR 3.36
- MACD
- SOL 0.01
- MNPR -0.03
- Stochastic Oscillator
- SOL 40.11
- MNPR 47.01
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has global Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. The company generates maximum revenue from Poland.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.